These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8372720)

  • 1. Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis.
    Nobunaga M; Yasuda M
    Agents Actions Suppl; 1993; 44():105-9. PubMed ID: 8372720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate.
    Yasuda M; Sakai K; Oribe M; Yoshioka K; Takahashi H; Ohtsuka E; Wada T; Shiokawa S; Yamamoto M; Ichibangase Y
    J Rheumatol; 1994 Jan; 21(1):44-50. PubMed ID: 8151586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
    Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
    Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment].
    Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T
    Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of rheumatoid arthritis with bucillamine-induced myasthenia gravis treated by immunoadsorption therapy].
    Sawa N; Ubara Y; Hara S; Hideyuki K; Tagami T; Yokoyama K; Takemoto F; Yamada A; Mori T; Mikami A; Tachibana S; Nakase K
    Ryumachi; 1999 Feb; 39(1):33-8. PubMed ID: 10332215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
    Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
    Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lung injury associated with bucillamine therapy].
    Negishi M; Kaga S; Kasama T; Hashimoto M; Fukushima T; Yamagata N; Tabata M; Kobayashi K; Ide H; Takahashi T
    Ryumachi; 1992 Apr; 32(2):135-9. PubMed ID: 1595005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
    Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Membranous glomerulonephritis probably related to bucillamine therapy in two patients with rheumatoid arthritis].
    Baba N; Nomura T; Sakemi T; Uchida M; Watanabe T
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):629-34. PubMed ID: 1920943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of bucillamine-induced pneumonitis].
    Tanaka H; Nakahara K; Goto K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Apr; 30(4):695-701. PubMed ID: 1405091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis.
    Kim HA; Song YW
    Rheumatol Int; 1997; 17(1):5-9. PubMed ID: 9194208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bucillamine-induced dermatomyositis-like clinical features in a patient with rheumatoid arthritis].
    Takeda T; Shimizu Y; Takeuchi M; Hashimoto S; Nagai C; Uchiyama S; Iwata M
    Rinsho Shinkeigaku; 2005 Jan; 45(1):45-8. PubMed ID: 15715001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of rheumatoid arthritis complicated with a pneumonitis during concomitant treatment with methotrexate and bucillamine].
    Miwa Y; Kaga S; Hanaoka R; Shiozawa F; Hanyuda M; Kasama T; Negishi M; Ide H
    Ryumachi; 2002 Feb; 42(1):70-5. PubMed ID: 11925909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with rheumatoid arthritis (RA) and proteinuria.
    Urata Y
    Clin Exp Nephrol; 2004 Sep; 8(3):288; author reply 289; discussion 290. PubMed ID: 15480911
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinicopathological evaluation and treatment of bucillamine induced membranous nephropathy].
    Kikuchi M; Saeki T; Ito S; In H; Saito T; Ueno M; Sato T; Suzuki S; Nakano M; Ozawa T
    Ryumachi; 1993 Jun; 33(3):215-22. PubMed ID: 8346463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study).
    Sagawa A; Fujisaku A; Ohnishi K; Mukai M; Yasuda I; Amasaki Y; Shimizu M; Ichikawa K; Ohsaki H
    Mod Rheumatol; 2011 Jun; 21(3):251-7. PubMed ID: 21188453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late phase II clinical study of M-5011C on rheumatoid arthritis--a multi-institutional double-blind, three group comparative, dose finding study].
    Ichikawa Y; Nakajima M; Azuma T
    Ryumachi; 1997 Dec; 37(6):851-66. PubMed ID: 9492574
    [No Abstract]   [Full Text] [Related]  

  • 18. [A long-term clinical analysis of the rheumatoid patients treated by a combination of GST and CCA].
    Minami M; Kaneda K
    Ryumachi; 1995 Oct; 35(5):780-91. PubMed ID: 8594657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranous glomerulonephritis in patients with rheumatoid arthritis.
    Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T
    Clin Ther; 1994; 16(6):1000-6. PubMed ID: 7697679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank.
    Frank M
    Future Microbiol; 2022 Feb; 17(3):157-159. PubMed ID: 35044238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.